pemafibrate
Kowa Pharmaceuticals
['cardio']
in a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, htg, and low hdl cholesterol levels who received pemafibrate, although tg, vldl cholesterol, remnant cholesterol, and apo c-iii levels decreased. #aha22 
The New England Journal of Medicine (https://t.co/YGfDrRsIhE) is the world’s leading medical journal and website.